[ad_1]
To the best of the service’s knowledge, there were no patients who experienced rare or extremely rare side effects, such as temporary facial paralysis or an acute allergic reaction.
“The most frequently reported adverse reactions were injection site pain, fatigue, headache, muscle and joint pain, fever and chills, nausea or vomiting, armpit pain or swelling, redness or swelling at the site of the injection”. 15 minutes Iistė Spokesperson Aistė Tautvydienė said.
Immunity does not develop immediately
According to her, most of the above reactions were mild to moderate in intensity and resolved within a few days.
“Some of them, such as fever, occurred more frequently after the second dose of the vaccine,” added A.Tautvydienė.
Photo by Žygimantas Gedvila / 15min / Aistė Tautvydienė
According to her, the service did not receive any reports that after the administration of the second dose of the COVID-19 vaccine, someone in Lithuania had been infected with the virus.
The IWT spokeswoman noted that immunity to COVID-19 does not develop immediately after the second dose.
Vaccinates may not be fully protected until 7-14 days after the second dose.
“Vaccines may not be fully protected until 7-14 days after the second dose.
Considering that the first vaccinated received the second dose of the vaccine on January 21 of this year at the earliest, the period during which the expected development of protection against the COVID-19 disease in the first vaccinated people has not yet passed ”, A.Tautvydienė fixed.
Vaccine safety continues to be monitored
There were no reports that someone who had received a second dose of COVID-19 had COVID-19.
It is true that the ministry said that the safety and benefits of both COVID-19 vaccines, Moderna and Pfizer and BioNTech, are still being studied.
Long-term safety and benefits for the entire European population will be investigated through independent vaccine safety studies.
“The safety of both vaccines currently on the market is being monitored further according to a previously agreed plan in ongoing post-authorization safety studies (safety will be monitored for 2 years).
Additional safety studies are also being carried out in Europe to monitor the use of vaccines in daily practice.
The long-term safety and benefits for the entire European population will be investigated by independent vaccine safety studies involving selected EU countries, ”said SAM.
„Reuters“ / „Scanpix“ nuotr./Vakcina nuo COVID-19
Clinics continue with booster shots
The Santara and Kaunas clinics also stated that they were unaware of such cases that someone who had been vaccinated against COVID-19 for the second time had recovered from the disease.
“Revaccination continues in the Kaunas clinics. According to data from January 26, 1,582 employees were vaccinated with the second dose of the vaccine,” said Karolina Račkauskienė, chief specialist of the Communication Service of the Kaunas Clinics of the Science Hospital. of Health of Lithuania.
The revaccination of COVID-19 also continues at the Santara Clinic.
“Of the employees of the personal medical care institutions for inpatients in the Vilnius region, whose vaccination is organized by the VUL Santara Clinics, 4,293 people have already received the second vaccine as of January 27.
Vaccination will continue on January 28 and more than 1,000 people will receive the second vaccine. None of them had serious side effects, “he said. 15 minutes delineated by the Clinical Communication Service.
Vaccination cannot cause an infection
As of January 28, the treatment facilities had vaccinated 15,756 people with a second dose of COVID-19.
At the moment, only the Pfizer and BioNTech vaccines are used for revaccination. Its efficiency is 95%.
Sigismund Gedvila / 15min photo / Pfizer
The coronavirus is not part of the Pfizer and BioNTech vaccines, that is, vaccination is prevented and vaccination cannot cause infection with the virus.
[ad_2]
